Enter your contact details & our Business Development
expert will circle back to address your request!
The global opioid use disorder market size was valued at USD 2,700 million in 2021 and is projected to reach around USD 5,200 million in 2030 exhibiting a CAGR of 8.5% in the forecasted period. The growth in the opioid epidemic in the U.S. along with the formation of government policies to regulate the problem are the major factors that boost the growth of the global opioid use disorder market. On the other hand, side effects related to opioid use disorder drugs estimated to hinder the growth of opioid use disorder market growth.
As per the CDC, in 2016, about 2.1 million Americans had OUD. The move from opioid abuse to opioid obsession consequences from drug-induced changes in the brain. The most normally abused opioids are oxycodone, hydrocodone, codeine, morphine, and fentanyl. Physical dependency is the most dangerous long-term effect; withdrawal symptoms occur if opioid use is sharply reduced. The number of opioid obsession cases is promptly increasing each year, making opioid requirement a severe public health problem. This factor can cause obsession of opioid drugs even after decline in pain. Thus, increase in the prevalence of chronic diseases predicted boost the demand of opioid use disorder drugs which increases the market growth. For instance, according to the report of the National Cancer Institute, in 2020, an expected 1,806,590 new incidences of cancer were detected in the U.S.
Existing treatments are founded on Medication-Assisted Treatment (MAT) with an opioid agonist or an opioid antagonist. It has been witnessed that people with OUD who follow detoxification with complete abstinence are extremely probably to deteriorate. MAT uses medications that decrease the negative effects of desires and removals without generating the euphoria that the original drug caused. MAT contains the use of drugs in blend with behavioural therapies and counselling, which is efficient in OUD handling and can help some individuals to withstand recovery.
Presently, there are relatively a few drugs that are permitted for the treatment of OUD. These can be separated into opioid agonists and antagonists. These drugs are generally available and have been genericized among several markets. But, a lot of these drugs have been reformulated and launched in latest years. Pipeline therapies are aiming on reformulations as well as an innovative mechanism of action to fight opioid addiction. The sale of these agents is anticipated to be among the major drivers of the opioid use disorder market over the forecasted period.
The COVID-19 outbreak is predicted to have a negative impact on growth of the global opioid use disorder market. The COVID-19 pandemic has strained healthcare systems of the globe. A vast number of clinics, hospitals across the world, were reorganized to upsurge the hospital capability for the patient detected with COVID-19. Furthermore, the postponement or termination of doctor appointments has strictly affected the market. Decline in the number of scheduled surgeries anticipated to decrease in demand of opioids which cause drop in the prevalence of opioid use disorder. Consequently, these factors are projected to hamper the growth of market.
Buprenorphine was the largest revenue-generating segment in 2021. Buprenorphine/naloxone sublingual tablets, buprenorphine sublingual tablets, and branded Suboxone are the extensively suggested drugs for OUD. Suboxone Film is the most recommended drug in the OUD market, owing to its exceptional clinical profile. High competence in managing obsession, with low possibility for abuse & moderately mild adverse impacts and its favourable formulary exposure, are factors that can be ascribed to the high assumption of this drug.
The first once-monthly product of Buprenorphine-Sublocade-is projected to be the largest and fastest-growing product over the forecasted period. It is a drug-device blend treatment that utilizes buprenorphine and the Atrigel delivery system in a pre-filled syringe. Sublocade reports the boundaries of remaining treatment by substituting daily oral medications with an injectable, thus creating diversion and misuse difficult and refining quality of life.
Drug Type Insights
The agonist segment ruled the opioid use disorder market share in 2021, and is anticipated to continue this trend across the forecasted period, due to increase in the prevalence of chronic pain, high incidence of opioid abuse and intensifying geriatric population prone to painful sickness. Though, antagonist segment is predicted to observe noteworthy growth through the opioid use disorder market forecasted period, owing to expansion in research & development expenses by major companies, strategic alliances among key corporations, and constant research on naltrexone drugs.
North America was the leading revenue-generating region in 2021 and is projected to express the same trend during the forecasted period. The opioid epidemic in the U.S. and Canada is among the major factors backing to the maximum market share of North America. Administrations are presenting numerous policies to regulate the emergency. For example, in January 2018, the U.S. administration propelled an awareness presenting campaign to fight opioid dependence.
Furthermore, the U.S. market is further projected to witness new products arriving the market over the forecasted period, such as Braeburn’s CAM-2038-additional buprenorphine subcutaneous preparation for, possibly, monthly injection. If permitted, it will have an advantage over Sublocade-Sublocade desires an introducing treatment with oral buprenorphine for 7 days till dose maintenance, while CAM-2038 will not have this requirement. This is expected to further increase the North America OUD market.
On the other hand, Asia-Pacific was the second-largest contributor in the market in 2021, and is anticipated to register fastest CAGR during the forecasted period, due to the figure of elderly populations, increase in the awareness about accessibility of healthcare services and upsurge in the number of chronic ailments.
Key Companies Insights
The market for opioid use disorder is moderately competitive. With the rising applications of opioid use disorder, new players are considering to enter the market. The companies are also involved in activities like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Opioid use disorder market, ultimately boosting the market growth. Some of the key companies working in the global Opioid use disorder market include:
• Indivior PLC
• Dr. Reddy
• Orexo AB
• Titan Pharmaceuticals, Inc.
• Pear Therapeutics
• Reckitt Benckiser Pharmaceuticals Inc.
• Mallinckrodt Pharmaceuticals
• BioDelivery Sciences International Inc.
• Viatris Inc. (Mylan N.V.)
• Hikma Pharmaceuticals PLC
• Other players
Some of the Recent Developments:
• In March 2022, Collegium Pharmaceutical, Inc. stated that it has successfully completed the acquisition of BioDelivery Sciences International Inc.
• In May 2020, Indivior PLC announced the sanction of Subutex from Swedish Medical Products Agency (MPA). Subutex extended release solution for injection, 100 and 300mg for substitution management of opioid dependence in adults and teenagers above 16 years of age.
By Drug Type
By Age Group
• 19 to 39
• 40 to 59
• Age 60 and Over
By Route of Administration
By Distribution Channel
• Hospital pharmacy
• Retail Pharmacy
• Online Pharmacy
• North America
o South Korea
• Latin America
o South Africa
o Saudi Arabia
Please fill form below:
99 WALL STREET #2124 NEW YORK, NY 10005